Breast Cancer
Conditions
Brief summary
This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase inhibitors or fulvestrant in the a/mBC community oncology setting.
Interventions
None listed
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who are represented in the Vector Oncology Data Warehouse who meet all of the following criteria will be eligible for inclusion in the study. * Female. * Diagnosis of female breast cancer with evidence of metastatic disease or advanced disease. * Diagnosis (confirmed by clinical review) of advanced or metastatic breast cancer at any time, defined as breast cancer at stage IIIb, stage IIIc, or stage IV or identified as having distant metastasis. * Indication in the record of ER or PR positive disease, or absence of any indication of ER and PR negative disease (ie, patients are eligible without affirmative indication of ER/PR+ status as long as ER/PR- indication is not present). * Receipt of a palbociclib plus aromatase inhibitor (AI) or palbociclib plus fulvestrant regimen on 2/3/2015 or later in the advanced and metastatic setting. Data collection will prioritize accrual of patients with 1L use of palbociclib plus AI and with 2L use of palbociclib plus fulvestrant before collecting other use of palbociclib users. * Age greater than or equal to 18 years at A/MBC diagnosis.
Exclusion criteria
-There are no
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients receiving various cancer treatment regimens | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Proportion of patients receiving each therapy sequence across lines | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Treatment persistence | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Progression Free Survival (PFS) | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Overall Survival (OS) | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Tumor response rate | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Proportion of patients that experience dose adjustment | A/MBC diagnosis through end of study (assessed up to 24 months) |
| Proportion of patients who discontinue therapy | A/MBC diagnosis through end of study (assessed up to 24 months) |
Countries
United States
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed